Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BIO 300 Oral Powder in Healthy Volunteers
NCT04650555Phase 1Completed
- Sponsor
- Humanetics
- Start
- Dec 2020
- Primary completion
- Jul 2021
- Modality
- Nanoparticles, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of BIO 300 in Acute Radiation Syndrome (ARS) (5 cohorts), sponsored by Humanetics. Primary endpoints: Adverse Events Related to BIO 300 Oral Powder, Change in ECG QTc Interval and 2 more. Started Dec 2020; status: completed.
02
Drugs
BIO 300
03
Conditions
Acute Radiation Syndrome (ARS)
Beyond the preview
Go deeper on NCT04650555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04650555.